HC Wainwright Has Bullish Forecast for REGENXBIO Q1 Earnings
Analysts at HC Wainwright increased their Q1 2025 earnings estimates for shares of REGENXBIO in a note issued to investors on ...
The Pharma Letter17h
Regenxbio’s RGX-202 continues to show promise in DMD
US gene therapy company Regenxbio has reported new, positive interim data from two additional patients in the Phase I/II ...
PipelineReview.com23h
REGENXBIO reports positive biomarker data from AFFINITY DUCHENNE trial of RGX-202 gene therapy
ROCKVILLE, MD, USA I March 19, 2025 I REGENXBIO Inc. (Nasdaq: RGNX) today reported new, positive interim data from two additional patients in the Phase ...
GlobalData on MSN18h
Regenxbio’s DMD gene therapy drives 122.3% biomarker uptick in three-year-old
Regenxbio has reported positive interim data from the Phase I/II portion of its Affinity Duchenne study, which is examining ...